(Total Views: 760)
Posted On: 02/23/2021 5:46:44 PM
Post# of 153888
At one point FDA Janet Woodcock says: "Very soon we should open up the monoclonal antibodies to direct ordering so they can be ordered by anyone who has capacity to administer them."
https://www.webmd.com/coronavirus-in-context/...ck-updates
It's possible it was referring to the IV monoclonals, but the comment is suspiciously similar to how leronlimab would be ordered.
Also says: "have a very good pipeline" of monoclonals.
She says that hundreds of repurposed drugs are being studied for Covid-19 treatment.
For the inflammatory stage, immunomodulatory agents. Doesn't that sound like leronlimab?
But, she did say that for therapeutic agents, only 5% of trial arms give us an answer that is actionable. But, because they are talking to and negotiating with the FDA, isn't is likely leronlimab is within that 5%?
https://www.webmd.com/coronavirus-in-context/...ck-updates
It's possible it was referring to the IV monoclonals, but the comment is suspiciously similar to how leronlimab would be ordered.
Also says: "have a very good pipeline" of monoclonals.
She says that hundreds of repurposed drugs are being studied for Covid-19 treatment.
For the inflammatory stage, immunomodulatory agents. Doesn't that sound like leronlimab?
But, she did say that for therapeutic agents, only 5% of trial arms give us an answer that is actionable. But, because they are talking to and negotiating with the FDA, isn't is likely leronlimab is within that 5%?
(11)
(0)
